Compare DVN & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVN | ZBH |
|---|---|---|
| Founded | 1971 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 18.7B |
| IPO Year | N/A | N/A |
| Metric | DVN | ZBH |
|---|---|---|
| Price | $36.24 | $94.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 20 |
| Target Price | $43.37 | ★ $107.84 |
| AVG Volume (30 Days) | ★ 8.0M | 1.9M |
| Earning Date | 02-17-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.79% | 1.04% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.24 | 4.03 |
| Revenue | ★ $16,554,000,000.00 | $8,010,900,000.00 |
| Revenue This Year | $13.18 | $7.98 |
| Revenue Next Year | N/A | $5.21 |
| P/E Ratio | ★ $8.12 | $22.98 |
| Revenue Growth | ★ 13.94 | 5.47 |
| 52 Week Low | $25.89 | $85.33 |
| 52 Week High | $38.88 | $114.44 |
| Indicator | DVN | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 57.08 |
| Support Level | $34.23 | $89.50 |
| Resistance Level | $38.19 | $95.32 |
| Average True Range (ATR) | 1.06 | 1.97 |
| MACD | -0.16 | 0.55 |
| Stochastic Oscillator | 49.67 | 84.37 |
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two-thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2024, Devon reported net proved reserves of 2.2 billion barrels of oil equivalent. Net production averaged roughly 848,000 barrels of oil equivalent per day in 2024 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.